Alterations of the circadian clock have been linked to cancer development. Puram et al. (in this issue) now uncover differential requirements between healthy hematopoietic and diseased leukemic stem cells for core circadian transcription factors, wherein leukemic cells depend on the clock machinery for survival and growth.
The mammalian circadian clock is composed of an integrated collection of transcriptional circuits that oscillate with a 24 hr periodicity in order to maintain rhythms in sleep-wake cycles, metabolism, endocrine input, and cellular proliferation (Cermakian and Sassone-Corsi, 2000; Miller et al., 2007) . In recent years, circadian rhythms have emerged as an important long-range regulatory component of hematopoiesis. Most roles for circadian rhythms, however, have thus far been attributed to extrinsic (nonautonomous) mechanisms regulating the healthy hematopoietic microenvironment (Hanoun et al., 2015) . In this context, oscillating adrenergic activity within the bone marrow controls the rhythmic release of hematopoietic stem cell (HSC) from their niche to the periphery (Hanoun et al., 2015; Mé ndezFerrer et al., 2008) . Genetic deletion of core circadian transcription factors (TFs) Bmal1 and Clock results in significantly shorter lifespan and premature aging, but there is thus far no compelling evidence that the expression of clock genes in HSCs plays a significant role in their maintenance.
The circadian clock transcriptional system is intricately regulated at the epigenetic level (Cermakian and Sassone-Corsi, 2000) and was shown to regulate cellular proliferation (Miller et al., 2007) , making it a potential driver for cancer. Indeed, altered circadian rhythms in shift workers are associated with increased cancer risk (Masri et al., 2015) . Core circadian clock TFs have been shown to act as tumor-suppressors, where deletion of Period2 promotes cancer following exposure to irradiation (Fu et al., 2002) , and epigenetic silencing of Bmal1 was described in both B cell lymphoma and acute lymphocytic and myeloid leukemias (Taniguchi et al., 2009) . However, other studies describe a more complex scenario between circadian transcriptional circuitry and cancer, attributed to experimental inconsistencies (Antoch et al., 2013) . Thus, even though associations between circadian rhythms and cancer have been established, the mechanisms linking transcriptional control of clock genes and hematopoietic cancers are not well understood. In this issue of Cell, an elegant study by Ebert and co-workers (Puram et al., 2016) demonstrates that the core circadian TFs Bmal1 and Clock are required for leukemia stem cell (LSC) growth and selfrenewal, establishing a novel pro-tumorigenic role for circadian clock genes in acute myeloid leukemia (AML).
Through investigations to identify essential TF mediating LSC self-renewal, Ebert and co-workers perform an in vivo RNAi screen using a MLL-AF9 AML quaternary transplantation model with genetically and functionally defined LSCs (Krivtsov et al., 2006) . In this model, serial transplantation enriches for LSCs, generating short latency and high penetrance of leukemia suitable for in vivo screening. In addition to well established regulators of LSC function, the RNAi screen identifies the core circadian TFs, Bmal1 and Clock as the top candidate genes essential for AML function. Further experiments, disrupting the integrity of circadian rhythms in both murine and human AML by either shRNA silencing of Bmal1 and Clock or pharmacological inhibition of Bmal1 transcription, demonstrate that circadian disruption in AML cells induces myeloid differentiation and impairs cell-cycle progression. ChIP-seq analyses reveal that the BMAL1/CLOCK complex bound to multiple known circadian pathway genes and that both Per1 and Cry1, immediate Bmal1 and Clock targets, are essential genes promoting MLL-AF9 leukemia. Furthermore, the disruption of circadian TFs is associated with suppression of HoxA9, Meis1, and Ctnb1, key regulators of LSC self-renewal. Taken together, these novel findings identify the circadian system as a key transcriptional component for AML cell survival, most likely by regulating the self-renewal of LSCs.
It is notable that, although both healthy hematopoietic and leukemic cells exhibit robust intrinsic circadian oscillations that appear independent of central input from the suprachiasmatic nucleus, only leukemic cells are affected by disruption of circadian axis both in vitro and in vivo. Expression of Bmal1 in hematopoietic cells is dispensable for normal hematopoiesis and HSC self-renewal, differentiation, and multilineage commitment, whereas it is critical for LSC growth and disease propagation. The results thus suggest major differences in the reliance of normal and leukemic stem cells for TFs from the core molecular clock (Figure 1) .
Crosstalk of molecules that generate circadian rhythms with those involved in cell-cycle progression has been suggested (Miller et al., 2007) , and clock proteins may also be involved in cellcycle checkpoints involved in DNA damage and cancer. Are regulatory functions of Bmal1 and Clock in cellcycle progression coupled to circadian rhythmicity? It will be interesting to investigate whether chronic circadian disruption induced by shift work is sufficient to alter clock genes' basal functions and their requirements for leukemic cells. It is possible, for instance, that the Bmal1 and Clock acts as an upstream transcriptional activator of AML, regulating genes that promote LSC self-renewal and leukemic cell growth. Additionally, the interplay between the circadian clock and the leukemia epigenome will undoubtedly be a fertile ground for future investigations on its mechanisms regulating leukemogenesis (Masri et al., 2015) . The differential transcriptional wiring between normal and leukemic cells, however, offers exciting therapeutic opportunities by which the manipulation of circadian rhythms in AML may sensitize leukemic cells to conventional anti-cancer therapies while preserving normal hematopoiesis. The newly found addiction of AML to the clock machinery also offers new avenues for chronotherapies aimed at the eradication of LSCs to prevent disease relapse. At steady state, extrinsic circadian rhythms regulate mobilization of normal hematopoietic stem cells (HSCs) from their niche by regulating HSC retention factors produced by stromal niche cells. In acute myeloid leukemia (AML), maintenance of leukemia stem cells (LSCs) depends on intrinsic expression of the circadian transcription factors Bmal1 and Clock, which control LSC self-renewal and proliferation. Thus, the core circadian transcription factors are pro-tumorigenic and essential for maintaining the leukemic state, yet dispensable for normal HSC function.
